Journal of Emergency Practice and Trauma

A clinical study investigating the three months prognosis of patients with ischemic stroke treated with recombinant tissue plasminogen activator (rt-PA) and its effective factors

Document Type : Original Article

Authors

Vahid Abbasi 1
Abolfazl Atalu 1
Afshan Sharghi 2
Fatemeh Taghvatalab 3

1 Department of Neurology, Ardabil University of Medical Sciences, Ardabil, Iran

2 Department of Community Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

3 Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

https://doi.org/10.15171/jept.2019.05
Abstract
Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has acceptable results in patients with stroke. This study aimed to evaluate the three months prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA).
Methods: This cross-sectional prospective study was conducted on 30 patients with cerebral ischemic stroke with the National Institutes of Health Stroke Scale (NIHSS) >5. Data such as demographic information, signs and symptoms, medical history, risk factors, focused neurological examination, and the NIHSS were collected for all patients. Then, all patients received 0.9 mg/kg of rt-PA as intravenous bolus doses and intravenous infusion under close monitoring in the emergency department. All patients were checked for necessary outcomes and also disability at the admission time, 7 days later and after three months all patients were checked again. All collected data were analyzed by appropriate tests using SPSS version 22.
Results: Of all patients, 63.3% were males and 36.7% were females. The mean age of the patients was 62.37 ± 12.62 years with a range of 40-91 years. The mean of NIHSS was 12.46 ± 4.28 at admission time, in day seven it was 8.06 ± 3.72 and in month three after treatment it was 3.62 ± 2.31. There was a significant relationship between age, place of residence and NIHSS. Thirty percent of patients had NIHSS more than 15 at admission time and after 7 days this rate reached to 10% and three months later it declined to 6.7%. These differences were statistically significant.
Conclusion: Intravenous thrombolytic therapy is associated with proper short term results in most patients with ischemic stroke.

Keywords

Prognosis
Ischemic stroke
Recombinant tissue plasminogen activator
Ardabil
Subjects
1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults
with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council,
Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral
Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115(20): e478-534. doi: 10.1161/circulationaha.107.181486.
2. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, et al. A prospective community-based study of stroke in Germany--the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke 1998; 29(12): 2501-6.
3. American Heart Association. Heart disease and stroken statistics—2011 update. Circulation 2011; 123(4):e18-209.
doi: 10.1161/CIR.0b013e3182009701
4. Yip TR, Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke 2007; 38(6): 1952-5. doi: 10.1161/strokeaha.106.479477.
5. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, et al. The Greater Cincinnati/Northern Kentucky Stroke
Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29(2): 415-21.
6. Marx J, Hockberger R, Walls R. Rosen’s Emergency Medicine - Concepts and Clinical Practice, 2-Volume Set. 8th ed. Philadelphia: Elsevier Health Sciences; 2013.
7. Hosseini AA, Sobhani-Rad D, Ghandehari K, Benamer HT. Frequency and clinical patterns of stroke in Iran -Systematic and critical review. BMC Neurol 2010; 10: 72. doi: 10.1186/1471-2377-10-72.
8. Smith RW, Scott PA, Grant RJ, Chudnofsky CR, Frederiksen SM. Emergency physician treatment of acute stroke with
recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med 1999; 6(6): 618-25.
9. Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissuetype
plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke 2014; 45(10): 3032-9. doi:
10.1161/strokeaha.114.005852.
10. Khosravi A, Farzadfard MT, Abdollahpour A. Frequency of stroke patients qualified for recombinant tissue plasminogen activator (r-TPA) injection and limitations in Zahedan 2016. Int J Basic Clin Pharmacol 2018; 7(1): 7-10. doi: 10.18203/2319-2003.ijbcp20175670.
11. Delavar Kasmaei H, Baratloo A, Nasiri Z, Soleymani M, Oraee Yazdani M. Recombinant tissue plasminogen activator administration in patients with cerebrovascular accident; a case series. Arch Neurosci 2015; 2(2): e23315. doi: 10.5812/archneurosci.23315.
12. Mojdehipanah H, Yazdi Z, Nasiri MS, Azizlo Z. Barriers to delivery of tissue plasminogen activator for patients with acute ischemic stroke. Feyz 2015; 19(2): 169-76. [InPersian].
13. Tintinalli JE, Krome RL, Ruiz E. Emergency medicine: a comprehensive study guide. Adv Emerg Nurs J 1992; 14(3): 74.
14. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for
acute ischemic stroke in the United States. Stroke 2005; 36(11): 2500-3. doi: 10.1161/01.str.0000185699.37843.14.
15. Meiner Z, Sajin A, Schwartz I, Tsenter J, Yovchev I, Eichel R, et al. Rehabilitation outcomes of stroke patients treated
with tissue plasminogen activator. PM R 2010; 2(8): 698- 702. doi: 10.1016/j.pmrj.2010.04.029.
16. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of
individual patient data from randomised trials. Lancet 2014; 384(9958): 1929-35. doi: 10.1016/s0140-6736(14)60584-5.
17. Pashapour A, Atalu A, Farhoudi M, Taheraghdam AA, Sadeghi Hokmabadi E, Sharifipour E, et al. Early and intermediate prognosis of intravenous thrombolytic therapy in acute ischemic stroke subtypes according to the causative classification of stroke system. Pak J Med Sci 2013; 29(1): 181-6. doi: 10.12669/pjms.291.2897.
18. Hatamabadi HR, Mansouri H, Asarzadegan F, Shojaee M. Barriers to on time delivery of thrombolytic therapy. Journal of Mazandaran University of Medical Sciences 2013; 23(102): 107-10. [In Persian].
19. Campbell BCV, Donnan GA, Lees KR, Hacke W, Khatri P, Hill MD, et al. Endovascular stent thrombectomy: the
new standard of care for large vessel ischaemic stroke. Lancet Neurol 2015; 14(8): 846-54. doi: 10.1016/s1474-
4422(15)00140-4.
Journal of Emergency Practice and Trauma
Volume 5, Issue 2
July 2019
Pages 47-50

  • Receive Date 19 January 2019
  • Revise Date 12 April 2019
  • Accept Date 13 April 2019

Home

Editor-in-Chief: Shahrad Tajoddini, MD

Guide for Authors

Submit Manuscript

Reviewers

Contact Us

Editorial board